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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal, degenerative neuromuscular disease
characterized by a progressive loss of voluntary motor activity. About 95% of ALS patients are in
"sporadic form"-meaning their disease is not associated with a family history of the disease. To date,
the genetic factors of the sporadic form of ALS are poorly understood.
Methods: We proposed a two-stage approach based on seventeen biological plausible models to
search for two-locus combinations that have significant joint effects to the disease in a genome-
wide association study (GWAS). We used a two-stage strategy to reduce the computational
burden associated with performing an exhaustive two-locus search across the genome. In the first
stage, all SNPs were screened using a single-marker test. In the second stage, all pairs made from
the 1000 SNPs with the lowest p-values from the first stage were evaluated under each of the 17
two-locus models.
Results: we performed the two-stage approach on a GWAS data set of sporadic ALS from the
SNP Database at the NINDS Human Genetics Resource Center DNA and Cell Line Repository
http://ccr.coriell.org/ninds/. Our two-locus analysis showed that two two-locus combinations--
rs4363506 (SNP1) and rs3733242 (SNP2), and rs4363506 and rs16984239 (SNP3) -- were
significantly associated with sporadic ALS. After adjusting for multiple tests and multiple models,
the combination of SNP1 and SNP2 had a p-value of 0.032 under the DomDom epistatic model;
SNP1 and SNP3 had a p-value of 0.042 under the Dom × Dom multiplicative model.
Conclusion: The proposed two-stage analytical method can be used to search for joint effects of
genes in GWAS. The two-stage strategy decreased the computational time and the multiple testing
burdens associated with GWAS. We have also observed that the loci identified by our two-stage
strategy can not be detected by single-locus tests.
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Background
Amyotrophic lateral sclerosis (ALS) is a fatal progressive
neurodegenerative disease that attacks nerve cells in the
brain and spinal cord resulting in muscle weakness and
atrophy. Although ALS is listed as a rare disease with a
prevalence of approximately 1 per 10,000, it is the most
common adult onset form of motor neuron diseases [1,2].
Epidemiological studies have showed that 1.5-5.3% of
cases are familial in nature [3-6]. The remaining 95% of
cases are not associated with a family history of the dis-
ease and seem to occur sporadically throughout the com-
munity. Several genes that cause familial ALS have been
identified [7-14], especially the SOD1 gene which is
believed to be responsible for 20% of familial ALS.
The identification of susceptibility genes of sporadic ALS
has been slow in arriving. The search for sporadic ALS
genes has generated a large number of candidate-gene
association studies [15-19]. To date, we do not have a
functional SNP or haplotype that has made a credible con-
tribution to our understanding of disease pathogenesis in
the way that the APOE-e4 allele does in Alzheimer disease
(AD) and the H1 MAPT haplotype does in parkinsonian
syndromes [20]. There is an urgent need to understand the
genetic architecture of sporadic ALS and ultimately to
develop novel drugs for this fatal disease. Sporadic ALS is
hypothesized to be a complex disorder in which the dis-
ease is modulated by variations in multiple genetic loci
interacting with each other and environmental exposures
[18]. The lack of major genes may be a reason for the
unsuccessful candidate gene studies which investigated
one gene at a time.
Recently, Schymick et al. made the first attempt to identify
genetic factors that might be relevant in the pathogenesis
of sporadic ALS by using a well-designed GWAS [1]. The
first stage single-marker analysis performed by Schymick
et al. showed that 34 SNPs had a p-value less than 0.0001
with the smallest one being 6.8 × 10-7. After adjusted by
permutation procedure, none of these SNPs reached the
significance level of 0.05. This finding suggests that the
ALS phenotype is not driven by a single powerful locus. By
testing one marker at a time, the first stage analysis made
the implicit assumption that susceptibility loci can be
identified through their independent, marginal contribu-
tions to the trait variability. More recently, other GWAS in
ALS have been conducted by different research groups
[21-24]. However, all these GWAS used single-marker
analysis. Recent human and animal studies of complex
diseases have identified susceptibility genes that margin-
ally contribute to a common trait, to a minor extent only
or not at all, but that interact significantly in combined
analyses [25-32]. Thus, methods that can account for joint
effects of genes may be appropriate for analyzing genome-
wide association data sets.
In this article, we used seventeen two-locus models to ana-
lyze the previously published genome-wide association
data for ALS. We found that three SNPs were significantly
associated with sporadic ALS. After we observed the signif-
icant two-locus combinations, we further estimated the
impact (relative risk and odds ratio) of each of the two-
locus combinations on sporadic ALS. It has been recog-
nized that the traditional method will over estimate the
odds ratio or relative risk in GWAS [32,33]. Recently, Zoll-
ner and Pritchard proposed a new method to estimate
penetrance and then odds ratio and relative risk [32].
Through extensive simulation studies, Zollner and Pritch-
ard showed that the estimations of odds ratio and relative
risk by their method were not upward biased. By modify-
ing Zollner and Pritchard's method, we proposed a new
method to estimate two-locus penetrance, and then esti-
mate the odds ratio, relative risk and sample size needed
to replicate the findings for this rare disease.
Methods
In this section, we will give details of the data set and
describe a new analytical method to analyze this data set.
The Data Set from GWAS for Sporadic ALS
Schymick et al. have made their data set publicly available
through the website of the National Institute of Neurolog-
ical Disorders and Stroke (NINDS) Human Genetics
Resource Center at the Coriell Institute http://ccr.cori
ell.org/ninds[1]. The data set contained 555,352 unique
SNPs across the genome in 276 patients with sporadic ALS
and 271 neurologically normal controls. The 555,352
SNPs were carefully chosen tagging SNPs from phase I and
II of the HapMap Project. The sampled individuals were
all non-Hispanic white Americans. There were 102
females and 174 males in cases, and 142 females and 129
males in controls. All sampled individuals had a more
than 95% genotype call rate. The average call rate across
all samples was 99.6%. Of the 555,352 SNPs studied, the
genotype call rate was greater than 99% for 514,088 (rep-
resenting 92.6% of all SNPs assayed) and greater than
95% for 549,062 (98.9%) SNPs. The phenotype file of
this data set contained the status of sporadic ALS, age of
onset, site of onset (bulbar-onset, upper-limb-onset, and
lower-limb-onset), gender, and smoking status among
other information.
Statistical Analysis
Two-locus Analysis Based on Seventeen Two-locus Models
In this article, we used seventeen two-locus models to ana-
lyze the genome-wide association data. For each SNP, we
called one allele a high-risk allele if its frequency in cases
was larger than the frequency in controls. For SNP A with
alleles A, a and SNP B with alleles B, b, Figure 1 and 2 give
eight epistatic two-locus models and nine multiplicative
two-locus models with high-risk alleles A and B, respec-BMC Medical Genetics 2009, 10:86 http://www.biomedcentral.com/1471-2350/10/86
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tively. Some of the eight epistatic two-locus models have
been used and discussed by Xiong et al. and Zhao et al.
[34,35]. The multiplicative models that are good approxi-
mations of additive models have been discussed by
Hodge and Risch [36,37].
Under each of the epistatic models, the nine two-locus
genotypes were divided into two groups: high-risk geno-
type group and low-risk genotype group. For example,
under the model DomDom, the high-risk group was GH
= {aAbB, AAbB, aABB, AABB} and the low-risk group was
GL = {aabb, aAbb, AAbb, aaBB} For the eight epistatic mod-
els, we used one degree of freedom (df) 2 test statistic
given by
to test for association of two-locus joint effects, where  ,
, and   denote the frequencies of the high-risk geno-
type group in cases, controls and the pooled sample (cases
and controls are pooled together).
For the nine multiplicative models, we constructed a two-
locus association test as follows. Let P(Disease|g) denote
the penetrance of two-locus genotype combination g =
(g1, g2), where g1 and g2 are the genotypes in the first and
second markers, respectively. Let 0 denote the logarithm
of the penetrance of genotypes with a relative risk of 1 in
the models (see Figure 2) and 1 = log, where  is the rel-
ative risk given in Figure 2. Then, the nine multiplicative
models can be described by the following log linear
model log P(Disease|g) = 0 + 1X, where X = x1 + x2, x1 is
the numerical code of g1 and is given by
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Eight two-locus epistatic models Figure 1
Eight two-locus epistatic models. A and B are the high-risk alleles in the two markers.  and  are the penetrance. : two-
locus genotypes with both high-risk genotypes at SNP A and SNP B are high-risk genotypes. : two-locus genotypes with at 
least one high risk genotype at SNP A or SNP B are high-risk genotypes.
Nine two-locus multiplicative models Figure 2
Nine two-locus multiplicative models. A and B are the 
high-risk alleles in the two markers. The symbol in each cell 
denotes the relative risk of this cell.  = 2,  = 3 and  = 4.
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for a dominant, recessive or multiplicative model, respec-
tively; x2 is similarly defined as the numerical code of g2.
Under the log linear model log P(Disease|g) = 0 + 1X, 1
= 0 means that all the genotypes have the same penetrance
which implies that   = 1. So a test of the association
between the disease and the two loci under the nine mul-
tiplicative models is equivalent to a test of the null
hypothesis H0: 1 = 0. For the ith individual, let yi denote
the trait value (1 for diseased individual and 0 for normal
individual) and Xi denote the numerical code of the geno-
type (X in the log linear model). The score test statistic is
given by
where N is the sample size,   is the average of X1,..., XN,
and   is the average of y1,..., yN. Under the null hypothe-
sis, Tscore follows a 2 distribution with 1 df. Note that
under each of the two-locus epistatic models, if we code X
= 1 for a high-risk genotype group and X = 0 for a low-risk
genotype group, then Tepi = Tscore.
The method to search for significant two-locus combina-
tions for each of the seventeen models has the following
two steps:
Step 1: For each SNP, let n and m denote the number
of individuals in cases and controls (different SNPs
may have a different number of cases and controls due
to missing genotypes). Let n1, n2, n3 and m1, m2, m3
denote the number of three genotypes in cases and
controls, respectively. The 2 df genotypic test statistic
is given by
where   and  . We applied this test statistic
to each SNP, calculated the corresponding p-value, and
returned M SNPs with the smallest p-values (M = 1,000
was used in this article).
Step 2: Under each of the seventeen two-locus models,
we applied a two-locus association test to each of the
L  two-locus combinations among the M  retained
SNPs, where L = M(M-1)/2. For a two-locus epistatic
model given in figure 1, we used the two-locus test Tepi.
For a multiplicative model given in figure 2, we used
the score test Tscore. In this step, we got a p-value (called
raw p-value) for each of the L two-locus combinations
and each of the seventeen two-locus models.
A permutation procedure was used to adjust for multiple
tests and multiple models. In each permutation, we ran-
domly shuffled the cases and controls and repeated step 1
and step 2 based on the permuted data. We performed the
permutation procedure B times (B = 1,000 was used in
this article). For the ith model and lth two-locus combina-
tion (i = 1,...,17; l = 1,..., L), let pil and   denote the raw
p-values of the two-locus tests in step 2 based on the orig-
inal data and on the bth permutated data, respectively. Let
Then, for the ith model and lth two-locus combination, Pil,
the p-value adjusted for multiple tests and multiple mod-
els, was given by  .
A New Method to Estimate Penetrance
When a study identifies a locus or locus-combination that
shows evidence of association with a disease, it is com-
mon to estimate the impact of this locus or locus-combi-
nation on the phenotype of interest. This impact is often
expressed as an odds ratio. Estimation of the odds ratio is
also helpful for planning successful replication studies.
It is recognized that the traditional estimate of odds ratio
is up-biased because it is typically estimated for the locus
which was significant for association [32,33]. Recently,
Zollner and Pritchard proposed a new method to estimate
penetrance (odds ratio can be calculated based on the
penetrance) [32]. This new method was based on the like-
lihood of observed genotypes given that the locus was sig-
nificant for association. We modified Zollner and
Pritchard's method to estimate the penetrance and odds
ratio for two-locus combinations under each of the seven-
teen models given in Figure 1 and Figure 2. We use the
DomDom model given in Figure 1 as an example to
describe our method.
We use the following notation:
n, m: the number of cases and controls
the data D = {n1,..., n9; m1,..., m9}: the counts of nine two-
locus genotypes in cases and controls that constitute the
significant signal for association
(q1,..., q9): the population frequencies of the genotypes
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R: the relative risk of high-risk genotype combination to
low-risk genotype combination, R = /.
F: the population prevalence of the disease which is
assumed to be known.
Because ALS is a rare disease with F = 0.0001, we can esti-
mate qi from the sampled controls. Thus, we assume that
qi = (number of ith genotype in controls)/m is known in the
following discussion. In the DomDom model, the 5th,
6th, 8th and 9th genotype combination {(aA, bB), (AA, bB),
(aA, BB), (AA, BB)} is the high-risk genotype combina-
tion, and the combination of the other genotypes is the
low-risk genotype combination. Let qH = q5 + q6 + q8 + q9
denote the population frequency of the high-risk geno-
type combination. Then, the penetrance  and  (see Fig-
ure 1) can be calculated by
Thus, we have only one unknown parameter R Let S indi-
cate that the two-locus combination of interest shows sig-
nificant association. As described in the previous section,
we use a two-step approach for the two-locus analysis. A
significant association of the two-locus combination from
our two-step method means that each of the two loci
shows significant marginal association at level 1 in step 1
and significant joint association at level 2 in step 2. We
calculate the likelihood L(R) using the equation
where the data D = {n1,..., n9; m1,..., m9}. Since the data D
constitutes, by definition, a significant result, so D implies
S; hence Pr(S|D,R) = 1. If the value of L(R) can be calcu-
lated for each given R, we can obtain the MLE of R by
using a numerical optimization method (grid search was
used in this article). For each R, the numerator can be cal-
culated by the product of two multinomial distributions
where   if  the  kth genotype is a low-risk genotype;
 otherwise. The traditional method to estimate
the relative risk is to maximize Pr(D|R), the numerator in
the likelihood function L(R), without considering the fact
that the loci were significant for association. There is no
simple method to calculate the denominator Pr(S|R), the
power of our two-step test. We propose to use a simula-
tion method as described below. For a given R, the values
of  and  can be calculated by equation (1). When , ,
and qi are known, we can generate the two-locus geno-
types for n cases and m controls. Next, we will perform the
single-marker test and the two-locus test on the data set. If
the p-values of the two single-marker tests are less than 1
and the p-value of the two-locus test is less than 2, the
data set is said to be significant for association. We repeat
the process to generate the data sets many times (1 mil-
lion was used in this article). The proportion of significant
data sets is the estimate of Pr(S|R).
When the relative risk R has been estimated, the corre-
sponding estimates of  and  can be obtained from equa-
tion (1). The estimate of odds ratio of the high-risk
genotype group is given by  .
Following Zollner and Prichard, when there are more
than two genotype groups in the models such as these in
Figure 2, we define the odds ratio of one group to be the
odds of this group divided by the odds of the combina-
tion of the others. For example, there are three genotype
groups in the Dom × Dom model: low risk genotype
group  GL = {aabb}, middle risk genotype group GM =
{aabB, aaBB, aAbb, AAbb}, and high risk genotype group
GH = {aAbB, aABB, AAbB, AABB}. The odd ratio of the
high risk group ORH is the odds of GH divided by the odds
of GM  GL = {aabb, aabB, aaBB, aAbb, AAbb}. The odd
ratio of the low risk genotype group ORL is the odds of GL
divided by the odds of GM  GH = {aabB, aaBB, aAbb,
AAbb, aAbB, aABB, AAbB, AABB}. The odds ratio estima-
tion method will be the same as the case of two genotype
groups.
We used this new proposed method to estimate the odds
ratio for each of the two-locus combinations that showed
significant association with ALS in our two-locus analysis.
Based on the estimated penetrance, we used a simulation
method to estimate the sample size required to replicate
the findings with 80% power.
Results
We applied the two-locus analysis with two steps to the
genome-wide association data set for sporadic ALS. The
analysis was done for all genotypes with a call rate greater
than or equal to 95% (549,062 SNPs left). SNPs on the sex
chromosome were excluded in the analysis. In the first
step, we returned 1,000 SNPs with the smallest p-values
which corresponded to use a p-value cut-off 1 = 0.0023.
Then we tested all of the L = 499,500 two-locus combina-
tions under each of the seventeen models and used 1,000
permutations to evaluate the adjusted p-value for each of
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the two-locus combinations. After adjusting for multiple
tests and multiple SNPs, we found two two-locus combi-
nations with p-values less than 0.05. There were three
SNPs involved in the two two-locus combinations. The
details of the three SNPs are given in Table 1. The combi-
nation of SNP1 and SNP2 followed the DomDom
model with a p-value of 0.032 and SNP1 and SNP3 fol-
lowed the Dom × Dom model with a p-value of 0.042.
Table 2 gives the number of cases and controls in each of
the nine genotypes for the two two-locus combinations.
This table shows that the two two-locus combinations fit
the two models, DomDom and Dom × Dom. For exam-
ple, for SNP1 and SNP2, there were more cases than con-
trols for genotypes with at least one C allele at SNP1 and
at least one G allele at SNP2 and there were more controls
than cases for the other genotypes, which indicated that
SNP1 and SNP2 followed the DomDom model. In
Schymick et al.'s 2 df single-gene analysis [1], SNP1 was
ranked 1st with a p-value of 6.8 × 10-7, SNP 2 was ranked
10th with a p-value of 2.2 × 10-5, and SNP 3 was ranked 2nd
with a p-value of 1.7 × 10-6.
To estimate the impact of the two two-locus combinations
on sporadic ALS, we first estimated the penetrance of the
two-locus genotypes for each of the two two-locus combi-
nations under the corresponding model. Based on the
estimated penetrance, we estimated the relative risk, odds
ratio and sample size required to replicate the significant
findings with 80% power. We followed what is in Zollner
and Pritchard to obtain the 95% CI of the estimates [32],
that is, we generated 95% CI by comparing the likelihood
of all initial parameter points with the likelihood of the
point estimate. We included all points for which twice the
difference of log-likelihoods was < 95th percentile of a 2
distribution with 1 df. The estimations using both the pro-
posed method (adjusted estimates) and the traditional
method (unadjusted estimates) are summarized in Table
3. From this table, we can see that the unadjusted relative
risk, odds ratio were higher than the adjusted ones, and
the unadjusted sample size was smaller than the adjusted
one. These results were consistent with the finding of oth-
ers that the traditional estimates of relative risk and odds
ratio are up-biased [33,34].
Discussion
In this study we proposed a new analytical method that
considered joint effects of genes to analyze a data set from
the GWAS in sporadic ALS previously performed by
Schymick et al. [1]. Our analysis showed that the combi-
nation of SNP1 and SNP2 and the combination of SNP1
and SNP3 had significant effects on sporadic ALS.
Population stratification may lead to false-positive results.
We had also checked the population stratification prob-
lem in this data set using the following method. We ran-
domly chose 5,000 SNPs and got their p-values by a single
marker test. If population stratification did exist in this
Table 1: Information of the three SNPs. HRA: high-risk allele.
Allele frequency
SNP dbSNP ID Chromosome Location Gene Two alleles Controls Cases HRA
T 0.656 0.505
SNP1 rs4363506 10q26.13 Intergenic C 0.344 0.495 C
A 0.467 0.341
SNP2 rs3733242 4q21.1 SHROOM3 G 0.533 0.659 G
C 0.887 0.786
SNP3 rs16984239 2p24 Intergenic A 0.113 0.214 A
Table 2: (number of cases)/(number of controls) in each of the 
two-locus genotypes.
SNP1
SNP Genotype TT TC CC
SNP2 AA 11/23 14/37 3/7
AG 29/50 73/56 29/11
GG 23/45 65/24 28/16
SNP3 CC 33/95 95/89 37/30
CA 29/20 52/25 22/4
AA 1/3 5/3 1/0BMC Medical Genetics 2009, 10:86 http://www.biomedcentral.com/1471-2350/10/86
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data set, among the 5,000 p-values, there should be more
small p-values than expected under the uniform distribu-
tion. We used the one-side Kolmorgorov test statistic to
test if the 5,000 p-values followed a uniform distribution.
We repeated the procedure 10 times. The Kolmorgorov
test results showed that the p-values followed a uniform
distribution for all 10 replications, which indicated that
there was no population stratification in this data set. The
lack of population stratification in the data set was con-
sistent with the results of Schymick et al. [1]. Schymick et
al. studied the potential population structure in this data
by using STRUCTURE program [38]. The analysis with
STRUCTURE showed that there was no discernible differ-
ence in the population substructure between cases and
controls.
Significant associations claimed by association studies
often fail to be replicated. One possible reason is the over-
estimation of the effect in terms of the odds ratio or rela-
tive risk of the claimed variants. The overestimation of the
effect leads to the underestimation of the sample size
required to replicate the finding. In this article, we pro-
posed a new method to estimate the effect of claimed var-
iants. Based on the study of Zollner and Pritchard [32], we
expected that the estimates of odds ratio and relative risk
based on our proposed method would be nearly unbi-
ased. Thus we provided a useful tool to estimate the sam-
ple size for the follow up studies. For example, in order to
replicate the finding of SNP1 and SNP2 (the adjusted p-
value less than 0.05 under the Dom  Dom model) with
80% power, the sample size required is 800 estimated
Table 3: Penetrence, relative risk and odds ratio of the two-locus combinations.
Two-locus combination SNP1 and SNP2 SNP1 and SNP3
Penetrance Unadjusted
Pen()  =  0 . 4 8 F, Pen( ) = 0.40F;
Pen( ) = 1.78F. Pen()  =  1 . 0 2 F;
Pen()  =  2 . 6 0 F.
Adjusted
Pen()  =  0 . 5 1 F; Pen( ) = 0.44F;
Pen( ) = 1.73F. Pen()  =  1 . 0 3 F;
Pen()  =  2 . 4 3 F.
R and 95% CI Unadjusted 3.70, (2.85, 4.85) 2.55, (2.10, 3.15)
Adjusted 3.40, (2.40, 4.60) 2.35, (1.85, 2.95)
ORH and 95% CI Unadjusted 3.70, (2.85, 4.85) 3.37, (2.66, 4.34)
Adjusted 3.40, (2.40, 4.60) 3.05, (2.27, 4.01)
ORL and 95% CI Unadjusted 0.27, (0.21,0.35) 0.31, (0.23, 0.40)
Adjusted 0.29, (0.22, 0.42) 0.34, (0.25, 0.47)
SS and 95% CI Unadjusted 680, (480, 1040) 680, (460, 1040)
Adjusted 800, (500, 1500) 810, (520, 1520)
Note: There were two genotype combinations for SNP1 and SNP2,   = {TTAA, TCAA, CCAA, TTAG, TTGG} and   = {TCAG, CCAG, 
TCGG, CCGG}, three genotype combinations for SNP1 and SNP3,   = {TTCC},   = {TCCC, CCCC, TTCA, TTAA} and   = {TCCA, 
CCCA, TCAA, CCAA}. Pen(G) denotes the penetrance of G. R: relative risk. For SNP 1 and SNP2, R = pen() / pen()  =  /; for SNP1 and 
SNP3, R = pen() / pen( ) = pen() / pen()  =  . ORH (ORL): the odds ratio of the high-risk (low-risk) genotype group. SS: the sample 
size required to reach 80% power. Adjusted (Unadjusted): based on the penetrance estimated using the method proposed in this article (the 
traditional method). F is the prevalence and F = 10-4.
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using our proposed method instead of 680 estimated
using the traditional method.
Currently, several methods are available to test associa-
tions by taking joint effects of genes into account, such as
combinatorial searching method (CSM) and the multifac-
tor dimensionality reduction (MDR) method [39,40]. We
used the two-step CSM and MDR, replacing the two-locus
analysis test in step 2 by the CSM or MDR, to perform the
two-locus analysis. For the two-step MDR, we returned 50
SNPs instead of 1, 000 SNPs in the first step due to the
computational intensity. Both of the two-step CSM and
MDR found rs4363506 (SNP1) and rs12680546 (on
chromosome 8) as the best two-locus combination. How-
ever, the adjusted p-values of the two-step CSM and MDR
were 0.2 and 0.156. This means that the two-step CSM
and MDR did not find any two-locus combinations that
had significant association with sporadic ALS. The possi-
ble reasons are as follows: The genotypes of the two-locus
combinations we found (such as those given in Table 3)
are ordered. For example, penetrance of H1H2  pene-
trance of H1h2  penetrance of h1h2, where H1(h1) and
H2(h2) are the high-risk (low-risk) genotypes in the first
and second marker, respectively. The CSM and MDR
ignore the order of genotypes and therefore can group any
two genotypes together-in essence searching for the "best"
one among 21,146 different partitions of the two-locus
genotypes. By searching for irrelevant two-locus genotype
combinations, the CSM and MDR did not gain more
information but increased the noise level, and thus lost
power.
Conclusion
The proposed two-stage analytical method can be used to
search for two-locus joint effects of genes in GWAS. The
two-stage strategy significantly decreased the computa-
tional time and the multiple testing burdens associated
with GWAS. We have also observed that the three SNPs
identified by our two-stage strategy can not be detected by
single-locus tests.
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